Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

CDMO FDA inspections cover: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI.
Supplier Quality

CDMO: what it is, how FDA inspects contract facilities, and how to vet one

A CDMO develops and manufactures drugs for other companies under contract. This guide covers the definition, how FDA treats a contract facility as an extension of the sponsor under 21 CFR 200.10(b) and 211.22(a), and an Atlas analysis of FDA's inspection data: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI against 16.0% at other drug facilities, the 21 CFR Part 211 sections FDA cites most at CDMOs, five OAIs that became warning letters, and a five-step check of a CDMO's inspection record.

Read more
CMO vs CDMO vs CRO cover: FDA cited ISO 13485 supplier controls at 84 of 377 device inspections, 22.3%, in the first eight months of the QMSR.
Supplier Quality

Contract manufacturing organization: CMO vs CDMO vs CRO, and who FDA holds responsible

A contract manufacturing organization (CMO) makes, packages or tests drug and device products for the company that owns them. This guide explains how a CMO differs from a CDMO and a CRO, why the owner's quality unit keeps release responsibility under 21 CFR 211.22(a) and 200.10(b) while a CRO can take over sponsor duties in writing under 21 CFR 312.52, what a quality agreement with a CMO has to assign, how often FDA cited owners for weak outsourcing controls on 774 drug and 377 device inspections from January 2025 to October 2026, and what recent Form 483s at contract facilities show.

Read more
USP 71 sterility testing cover: 121 of 158 inspections citing 21 CFR 211.167(a), 76.6%, ended OAI against 16.8% of the rest.
CAPA & Quality Systems

USP 71 sterility test: methods, sample sizes, and what FDA cites

What the USP 71 sterility test is, how membrane filtration and direct inoculation differ, which media, temperatures and growth promotion organisms the chapter sets, how many containers to test per batch, when a positive result can be invalidated, how 21 CFR 211.167(a) and 610.12 apply, and what FDA cited at 158 drug inspections that recorded a 211.167(a) sterility or pyrogen testing citation between October 2008 and September 2026.

Read more
Water for injection cover: FDA cited 21 CFR 211.67 at 237 of 774 drug inspections, and 40.5% of those ended OAI.
CAPA & Quality Systems

Water for injection: WFI vs purified water specs and what FDA cites

What water for injection (WFI) is, how it differs from purified water on endotoxin, microbial action levels and production method, how a WFI generation, storage and distribution system is designed and monitored, and how FDA cited 21 CFR 211.48 (plumbing and potable water) and 211.67 (equipment cleaning and maintenance) at 774 Part 211 drug inspections from January 2025 to September 2026, with named Form 483 examples.

Read more
21 CFR Part 58: what FDA cites in GLP inspections, with 30 Form 483s and 109 observations, 19 forms citing the study director rule 58.33 and 6 GLP warning letters, 2025 to 2026.
GMP & GxP Compliance

21 CFR Part 58: good laboratory practice for nonclinical studies, and what FDA cites

What 21 CFR Part 58, FDA's good laboratory practice rule for nonclinical laboratory studies, requires: subparts A to K, the study director (58.33), the quality assurance unit (58.35), protocol and final report content, and record retention (58.195). Includes a GLP vs GMP comparison, the status of FDA's 2016 proposed GLP rule, and Atlas data on 30 Form 483s that cited Part 58 from January 2025 to June 2026 plus six GLP warning letters.

Read more
NDSRI limits: 26.5 to 1,500 ng per day by potency category, with FDA's interim limits extended to August 2027 and 0 of 510 drug CGMP warning letters naming a nitrosamine.
CAPA & Quality Systems

NDSRI: FDA acceptable intake limits, the CPCA categories, and what came after August 2025

What a nitrosamine drug substance-related impurity (NDSRI) is and how it differs from small-molecule nitrosamines such as NDMA and NDEA, the five potency categories and acceptable intake limits in FDA's August 2023 guidance, how ICH M7(R2) frames them, what FDA posted after the August 1, 2025 deadline, and what Atlas found when it searched the full text of 510 drug CGMP warning letters dated January 2021 to October 2026.

Read more
USP 788 cover: 10 and 25 micron particulate limits for injections, with 98 sterile drug inspections citing 211.113(b) and 54.1% of them ending OAI against 23.5% of the rest.
CAPA & Quality Systems

USP 788: particulate matter in injections, the limits, and what FDA cites

What USP 788 (particulate matter in injections) requires: Method 1 light obscuration and Method 2 microscopic particle count, the 10 µm and 25 µm limits per mL and per container, when Method 2 applies, and how USP 790 and USP 1790 cover visible particles. Adds Atlas data on 98 sterile drug inspections citing 21 CFR 211.113(b) from January 2025 to September 2026 and the 2026 warning letters that cited visual inspection programs.

Read more
Cleaning validation acceptance criteria cover: 10 ppm, 1/1000 dose and HBEL limits, with 237 of 774 FDA Part 211 drug inspections citing 21 CFR 211.67 and 40.5% of those ending OAI.
CAPA & Quality Systems

Cleaning validation acceptance criteria: 10 ppm, 1/1000 dose, HBEL and a worked MACO example

How cleaning validation acceptance criteria are set: the three legacy limits from FDA's 1993 inspection guide (10 ppm, 1/1000 of the dose, visually clean), the health-based exposure limit (PDE) approach in the EMA 2014 guideline and its 2018 questions and answers, a worked MACO to swab limit calculation with illustrative numbers, swab and rinse recovery, detergent and microbial limits, the three-run convention, and Atlas data on 21 CFR 211.67 citations and OAI outcomes at 774 drug inspections from January 2025 to September 2026.

Read more
Every USFDA warning letter to India, 2025 to 2026: 34 letters, 23 citing the quality unit, 16 to facilities already on Import Alert 66-40, and a 174-day median from inspection to letter.
Warning Letters & Enforcement

USFDA warning letters to Indian companies: all 34 CGMP letters from 2025 and 2026

A data roundup of the 34 FDA CGMP warning letters issued to facilities in India from January 1, 2025 to October 14, 2026: a full table by company, city and state, letter date, product type and main charges; counts by year and state; the violations FDA cites most often; the median gap from inspection to letter; India's OAI rate against the US; and links to each facility's Atlas inspection record where it is public.

Read more
OOS vs OOT cover: 1,525 FDA inspections cited an out-of-specification failure, and 34.2% of them ended OAI against 14.9% of the rest, Atlas data October 2026.
CAPA & Quality Systems

OOS vs OOT: what separates them, how FDA investigates OOS, and what investigators cite

The difference between an out-of-specification (OOS) result and an out-of-trend (OOT) result in pharma, where OOT guidance comes from when no FDA regulation defines it, the Phase I and Phase II investigation in FDA's OOS guidance with its retesting, resampling, averaging and outlier rules, how an OOS result feeds CAPA under 21 CFR 211.192, and what FDA cited at 1,525 drug inspections that recorded an OOS-related citation between October 2008 and September 2026.

Read more
ICH Q7 cover: GMP for active pharmaceutical ingredients section by section, with 26 FDA API warning letters from January 2025 to September 2026, 14 of them to Indian firms and 7 to Chinese firms.
GMP & GxP Compliance

ICH Q7: GMP for active pharmaceutical ingredients, section by section, with FDA data

ICH Q7 is the GMP guideline for active pharmaceutical ingredients. This guide lays out all 20 sections in one table, explains where Q7 starts to apply (the step where the API starting material enters the process), sets Q7 against 21 CFR Part 211, covers the 2015 Q7 questions and answers document, and reads 26 FDA API CGMP warning letters issued from January 2025 to September 2026 by country, inspection outcome and the Q7 sections behind each charge.

Read more
ISO 14971 risk management and the QMSR citations behind it: 377 device inspections, 39.5% citing risk clause 7.1 or 4.1.2, against 13.7% under the QSR in 2025.
Medical Devices

ISO 14971: the risk management process step by step, and what FDA cites under the QMSR

ISO 14971:2019 is the international standard for risk management of medical devices. This guide walks through its process clause by clause (plan, analysis, evaluation, control, overall residual risk, review, production and post-production), explains what the ISO/TR 24971:2020 guidance adds, and shows how the standard connects to FDA's QMSR, which incorporates ISO 13485 by reference from February 2, 2026 but does not incorporate ISO 14971. It adds Atlas data on what FDA investigators cited: risk management clauses at 149 of 377 device inspections with citations from February 4 to October 1, 2026 (39.5%), against 13.7% for the closest QSR section in 2025.

Read more